Charged Mesoporous Silica Nanoparticles for pH-Triggered Colon Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for colon-related diseases face challenges in achieving site-specific and controlled release, as they often suffer from variable transit times, premature drug release in the small intestine due to pH similarities, and incomplete conversion of prodrugs in the stomach and small intestine.
Innovation Solution
A positively charged mesoporous silica nanoparticle (MSN) with a silica matrix and quaternary ammonium functional groups is developed, allowing for controlled release and enhanced bioavailability by loading negatively charged bioactive compounds, which are attracted and released based on pH-dependent electrostatic repulsion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If time-dependent release formulation is used to delay drug release until colon, then drug can reach colon tissue, but precise control of colon site-specific release is not easy to achieve due to variable transit time
Solution Approach 1:
The patent applies parameter changes by utilizing pH as a controlling parameter for drug release. The mesoporous silica nanoparticle is designed to release drugs in response to pH changes, specifically targeting the pH environment of the colon (pH 6.5-7.0) while remaining stable in the stomach (pH 1.5-3.5) and small intestine (pH 5.5-6.5). This pH-dependent mechanism provides precise control over drug release location independent of variable transit times.
2Reliability
If pH-dependent release formulation is used based on pH values in GI tract, then drug can pass through stomach, but drug is prematurely released in small intestine because pH of small intestine and colon are not significantly different
Solution Approach 1:
The patent applies local quality by creating different functional regions within the mesoporous silica nanoparticle system. The nanoparticle surface is modified with specific functional groups (carboxyl, hydroxyl, or amine groups) that have different pKa values, creating localized pH-responsive regions. This allows the particle to remain stable at lower pH (stomach and small intestine) while triggering drug release at the higher pH environment of the colon, achieving site-specific delivery.
3Reliability
If prodrug formulation is used based on bacteria in colon, then active drug can be produced in colon, but portion of prodrug is converted into active form in stomach and small intestine containing lower amounts of same bacteria
Solution Approach 1:
The patent uses the pH environment as an intermediary mechanism to control drug release, replacing the biological intermediary (bacteria) with a physical-chemical intermediary (pH-triggered release). The mesoporous silica nanoparticle acts as a mediator that protects the drug during transit through the GI tract and releases it specifically in the colon based on pH differences, avoiding premature activation by bacteria in the stomach and small intestine.
4Quantity of substance
If mesoporous silica nanoparticle is used to incorporate large dosages of hydrophobic drugs, then loading capacity is improved, but controlled drug release and site-specific delivery remain challenging
Solution Approach 1:
The patent applies parameter changes by modifying the surface chemistry of the mesoporous silica nanoparticle with pH-responsive functional groups. This allows the nanoparticle to maintain high drug loading capacity for hydrophobic drugs while introducing pH-dependent controlled release capability. The functional groups (carboxyl, hydroxyl, or amine) change their charge state with pH, triggering drug release specifically in the colon environment.
Solution Approach 2:
The patent creates a composite material system by combining mesoporous silica nanoparticle core with pH-responsive functional groups on the surface. This composite structure integrates the high loading capacity of mesoporous silica with the controlled release properties of pH-sensitive functional groups, achieving both high drug loading and site-specific delivery to the colon.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MSN system achieves precise and sustained release of drugs in the colon, minimizing premature release in the stomach and small intestine, and optimizing bioavailability by utilizing pH-dependent mechanisms for controlled drug delivery.
Implementation Method 1
A previously unaddressed need exists in the art to address the deficiencies and inadequacies, especially in connection with establishment of a good bioavailability and controlled release drug delivery system
Implementation Method 2
allowing for controlled release and enhanced bioavailability by loading negatively charged bioactive compounds, which are attracted and released based on pH-dependent electrostatic repulsion
Data Source
AI summary
A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.